(Drug Name) (Drug Form) (Drug Strength)
show timeout overlay link

Your Session Is About to Expire

This online session is about to expire due to inactivity. Click Continue to return to page.

  • Weekly Ad

Cosentyx: Solution for injection (150mg)

Also see:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics

Visit Drug Summary Page
Drug Image file default-drug-image.png


What is this Medicine?

SECUKINUMAB (sek ue KIN ue mab) is used to treat psoriasis. It is also used to treat psoriatic arthritis and ankylosing spondylitis.

In-Depth Information

Cosentyx 150mg/mL Pre-Filled Syringe Solution for Injection

NDC: 000780639
  • Prescription Required
  • Not a Controlled Drug
    (CSA Schedule)
  • FDA Approved




FDA approved for the following conditions:
Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis

Storage Information
Refrigerate (between 36 and 46 degrees F)
Protect from light
Discard product if it contains particulate matter, is cloudy, or discolored
Store in carton until time of use
Do not freeze
Discard unused portion. Do not store for later use.
Cosentyx 150mg/mL Pre-Filled Syringe Solution for Injection

Reported Side Effects for Cosentyx 150mg/mL Pre-Filled Syringe Solution for Injection

Yeast Infection Incidence:
<1.0%*
Severity: MODERATE
Onset: DELAYED
Low White Blood Cells Incidence:
<1.0%*
Severity: MODERATE
Onset: DELAYED
Sinus Infection Incidence:
<1.0%*
Severity: MILD
Onset: DELAYED
Inflammatory Bowel Disease Incidence:
<1.0%*
Severity: MODERATE
Onset: DELAYED
Eye Infection Incidence:
<1.0%*
Severity: MODERATE
Onset: DELAYED
Antibody Formation Incidence:
<1.0%*
Severity: MODERATE
Onset: DELAYED
Elevated Hepatic Enzymes Incidence:
<1.0%*
Severity: MODERATE
Onset: DELAYED
Mouth Sores Incidence:
0.1-1.3%*
Severity: MODERATE
Onset: DELAYED
Runny Nose Incidence:
0.3-1.2%*
Severity: MILD
Onset: EARLY
Hives Incidence:
0.6-1.2%*
Severity: MILD
Onset: RAPID
Sore Throat Incidence:
1.0-1.2%*
Severity: MILD
Onset: DELAYED
Rhinitis Incidence:
1.4%*
Severity: MILD
Onset: EARLY
Loose Stools Incidence:
2.6-4.1%*
Severity: MILD
Onset: EARLY
Infection Incidence:
28.7-47.5%*
Severity: MILD
Onset: DELAYED
*This is an approximate aggregated range of reported side effects from clinical studies performed on this drug. Your experience with this drug may be different.
Pregnancy & Lactation Information
FIRST Trimester

Class B - Animal studies have revealed no evidence of harm to the fetus, however, there are no adequate and well-controlled studies in pregnant women. OR Animal studies have shown an adverse effect, but adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus in any trimester.

SECOND Trimester

Class B - Animal studies have revealed no evidence of harm to the fetus, however, there are no adequate and well-controlled studies in pregnant women. OR Animal studies have shown an adverse effect, but adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus in any trimester.

THIRD Trimester

Class B - Animal studies have revealed no evidence of harm to the fetus, however, there are no adequate and well-controlled studies in pregnant women. OR Animal studies have shown an adverse effect, but adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus in any trimester.

Lactation

Caution - Not enough information is available to rule out harm to infants when this drug is taken by nursing mothers.


Learning More About
Visit the Drug Summary page where you can:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics
Learn More
Patient Experiences with Cosentyx

Be the first to share your experience!

We want to help our customers stay educated about the medications they are taking. Submit your own observations and experiences to benefit others.

Average Scores
Easy to Take 
0 / 5
0 / 5
Works as Intended 
0 / 5
0 / 5
Tolerable 
0 / 5
0 / 5